Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.
The aminoglycosides and cyclic polypeptides are essential drugs in the treatment of multidrug-resistant tuberculosis, underscoring the need for accurate and reproducible drug susceptibility testing (DST). The epidemiological cutoff value (ECOFF) separating wild-type susceptible strains from non-wild-type strains is an important but rarely used tool for indicating susceptibility breakpoints against Mycobacterium tuberculosis. In this study, we established wild-type MIC distributions on Middlebrook 7H10 medium for amikacin, kanamycin, streptomycin, capreomycin, and viomycin using 90 consecutive clinical isolates and 21 resistant strains. Overall, the MIC variation between and within runs did not exceed +/-1 MIC dilution step, and validation of MIC values in Bactec 960 MGIT demonstrated good agreement. Tentative ECOFFs defining the wild type were established for all investigated drugs, including amikacin and viomycin, which currently lack susceptibility breakpoints for 7H10. Five out of seven amikacin- and kanamycin-resistant isolates were classified as susceptible to capreomycin according to the current critical concentration (10 mg/liter) but were non-wild type according to the ECOFF (4 mg/liter), suggesting that the critical concentration may be too high. All amikacin- and kanamycin-resistant isolates were clearly below the ECOFF for viomycin, and two of them were below the ECOFF for streptomycin, indicating that these two drugs may be considered for treatment of amikacin-resistant strains. Pharmacodynamic indices (peak serum concentration [Cmax]/MIC) were more favorable for amikacin and viomycin compared to kanamycin and capreomycin. In conclusion, our data emphasize the importance of establishing wild-type MIC distributions for improving the quality of drug susceptibility testing against Mycobacterium tuberculosis.
Swedish Institute of Disease Control (SMI), Stockholm, Sweden.
P
P
Juréen
K
K
Angeby
E
E
Sturegård
E
E
Chryssanthou
C G
CG
Giske
J
J
Werngren
M
M
Nordvall
A
A
Johansson
G
G
Kahlmeter
S
S
Hoffner
T
T
Schön
D000617:Aminoglycosides / Q000494:pharmacology*; D000995:Antitubercular Agents / Q000494:pharmacology*; D003470:Culture Media / Q000737:chemistry; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D010456:Peptides, Cyclic / Q000494:pharmacology*; D014376:Tuberculosis / Q000382:microbiology*
D000617:Aminoglycosides; D000995:Antitubercular Agents; D003470:Culture Media; D010456:Peptides, Cyclic